Dr. Brenda Cooperstone has over 25 years of pharmaceutical drug development experience. Through 2023, Dr. Cooperstone was Senior Vice President and Chief Development Officer for Rare Disease at Pfizer Inc. and Site Leader for Pfizer’s Pennsylvania campus. As Chief Development Officer, she was responsible for the strategic growth and advancement of the Pfizer development portfolio for the Rare Disease Business, building advanced technology platforms like Gene Therapy. Prior to this role, Dr. Cooperstone held varied leadership positions at Pfizer and Wyeth in both Clinical Development and Global Medical Affairs with oversight of a wide range of therapeutic areas, including both small and large molecules in early through late phase development and in-line support. Dr. Cooperstone is currently a member of the Board of Director for Senti Biosciences, Gandeeva Therapeutics and Lexeo Therapeutics as well as advisor to early and clinical stage biotechnology companies.
Dr. Cooperstone earned her M.D. from McGill University, completed her residency in pediatrics at the Montreal Children’s Hospital, her clinical fellowship in pediatric nephrology at Children’s Hospital of Philadelphia and a research fellowship at the University of Pennsylvania, Renal Electrolyte Division. She is certified by the American Board of Pediatrics and Pediatric Nephrology and the Royal College of Physicians and Surgeons of Canada, Pediatrics. Dr. Cooperstone was on staff at Scottish Rite Children’s Hospital in Atlanta, GA as a Pediatric Nephrology before joining the pharmaceutical industry.